A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
Pharmacology, Toxicology and Pharmaceutical Science
1
2%
Other
3
7%
Unknown
24
53%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2019.
All research outputs
#4,359,475
of 34,377,743 outputs
Outputs from Cancer (0008543X)
#3,998
of 18,981 outputs
Outputs of similar age
#67,101
of 393,305 outputs
Outputs of similar age from Cancer (0008543X)
#49
of 135 outputs
Altmetric has tracked 34,377,743 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 18,981 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,305 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 135 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
